Trial Profile
Phase 1a, First-In-Human, Dose-Escalation Study of (+)-SJ000557733 (SJ733), an Oral, Novel Inhibitor of Plasmodium Falciparum Plasma Membrane Protein PfATP4
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Sep 2020
Price :
$35
*
At a glance
- Drugs SJ 733 (Primary) ; Cobicistat
- Indications Malaria
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms BUZZOFF
- 01 Aug 2020 Results published in The Lancet Infectious Diseases
- 28 Dec 2018 Status changed from recruiting to completed.
- 31 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Nov 2018.